Yuankai Shi, MD
Aerospace Center Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Cancer Institute/Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Yuankai Shi, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:05 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07806500 · Phase Ib Study of Oral R01 Monotherapy in Advanced Solid TumorsBeijing Anjianxi Bio-Medical Technology Co., Ltd. · not yet recruiting · Squamous Cell Lung Cancer, Gastric Cancer, Esophageal Cancer · principal investigator
- Ph2NCT06886139 · A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.Zhejiang Teruisi Pharmaceutical Inc. · not yet recruiting · CD20-positive Diffuse Large B-Cell Lymphoma · principal investigator
- Ph1NCT06565689 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012Excyte Biopharma Ltd · recruiting · Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph1NCT06410092 · Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001Sound Biopharmaceuticals Ltd. · recruiting · Solid Tumor · principal investigator
- Ph2NCT05948813 · TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesTYK Medicines, Inc · recruiting · NSCLC, EGFR Activating Mutation, Brain Metastases · principal investigator
- Ph1NCT05395533 · A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.Zhejiang Teruisi Pharmaceutical Inc. · active not recruiting · CD20-positive B-cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT05146219 · Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR MutationTYK Medicines, Inc · completed · NSCLC, EGFR Activating Mutation, Brain Metastases · principal investigator
- Ph2NCT04999800 · Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1Shi Yuankai · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT04857164 · Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in ChinaYuankai Shi · recruiting · Head and Neck Squamous Cell Carcinoma · principal investigator
- N/ANCT04740996 · Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in ChinaShi Yuankai · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT04620837 · Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line ChemotherapyChinese Academy of Medical Sciences · unknown · Small Cell Lung Carcinoma · principal investigator
- Ph2NCT04600947 · Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaTaizhou HoudeAoke Biomedical Co., Ltd. · unknown · Primary Mediastinal Large B-Cell Lymphoma (PMBCL) · principal investigator
- Ph2NCT04518137 · A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)Shanghai Antengene Corporation Limited · terminated · Advanced Solid Tumors · principal investigator
- Ph3NCT04416035 · A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLCZhejiang Teruisi Pharmaceutical Inc. · unknown · Advanced Non-squamous Non-small-cell Lung Cancer · principal investigator
- Ph2NCT04146181 · Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell CarcinomaSinocelltech Ltd. · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph3NCT04146402 · SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaSinocelltech Ltd. · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph1NCT04121286 · A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in ChinaAllist Pharmaceuticals, Inc. · completed · Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma · principal investigator
- Ph1/Ph2NCT04110301 · MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)Beijing Mabworks Biotech Co., Ltd. · unknown · Follicular Lymphoma and Marginal Zone Lymphoma · principal investigator
- Ph2NCT03904719 · CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)AnewPharma · unknown · Small Cell Lung Cancer · study chair
- Ph2NCT03874741 · SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell CarcinomaSinocelltech Ltd. · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT03744208 · SCT200 Injection in Patients With Head and Neck Squamous Cell CarcinomaShi Yuankai · unknown · Head and Neck Squamous Cell Carcinoma · principal investigator
- Ph2NCT03713372 · Safety and Efficacy of SCT200 in Head and Neck Squamous Cell CarcinomaSinocelltech Ltd. · unknown · Head and Neck Cancer · principal investigator
- Ph2NCT03693547 · Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer(NSCLC)Beijing Biostar Pharmaceuticals Co., Ltd. · completed · Advanced Non-small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT03639467 · Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal CarcinomaChinese Academy of Medical Sciences · unknown · Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma · principal investigator
- Ph1/Ph2NCT03565003 · A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in ChinaJacobio Pharmaceuticals Co., Ltd. · completed · Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer · study chair
- Ph1/Ph2NCT03420079 · A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive MutationAhon Pharmaceutical Co., Ltd. · unknown · Lung Cancer · principal investigator
- Ph2NCT03405272 · Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRCSinocelltech Ltd. · unknown · Metastatic Colorectal Cancer · principal investigator
- Ph3NCT03058094 · A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKIHangzhou ACEA Pharmaceutical Research Co., Ltd. · withdrawn · NSCLC · principal investigator
- Ph1NCT02914990 · Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC PatientsBetta Pharmaceuticals Co., Ltd. · completed · Non-Small Cell Lung Cancer · study chair
- Ph1NCT02809573 · Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma PatientsChipscreen Biosciences, Ltd. · completed · Peripheral T-cell Lymphoma · principal investigator
- Ph1NCT02478866 · Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid TumorsBetta Pharmaceuticals Co., Ltd. · completed · Solid Tumors · study chair
- Ph1NCT02066870 · Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKIBetta Pharmaceuticals Co., Ltd. · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph1NCT01772732 · Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLCJiangsu Simcere Pharmaceutical Co., Ltd. · unknown · Non-small Cell Lung Cancer · principal investigator
- Ph2NCT01024712 · Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung CancerCancer Institute and Hospital, Chinese Academy of Medical Sciences · unknown · Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:05 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.